Brilinta
Acute Coronary Syndrome
60 · 90mg
utilized to manage acute coronary syndrome to mitigate platelet activity.
Ticagrelor is the medicine ingredient covered on this page. The catalog summary describes it as follows: Inhibits platelet aggregation to prevent blood clot formation, often used to manage cardiovascular conditions. The products below may vary by brand, strength, form, release profile, or combination ingredients, so use the listing as a checkpoint before comparing it with a prescription or product label.
Acute Coronary Syndrome
60 · 90mg
utilized to manage acute coronary syndrome to mitigate platelet activity.
Blood-thinning medicines are useful because they reduce clot risk, but that same effect makes bleeding checks central.
For Ticagrelor, the starting fact is its catalog description: Inhibits platelet aggregation to prevent blood clot formation, often used to manage cardiovascular conditions. That sentence tells you what to verify next - the diagnosis, the product form, and the instructions that come with the exact listing.
Black stools, vomiting blood, coughing blood, severe headache, unexplained bruising, major falls, or uncontrolled bleeding need urgent advice.
Do not stop anticoagulants or antiplatelets abruptly unless a clinician gives a clear plan.
Tell a healthcare professional about current medicines, supplements, allergies, pregnancy or breastfeeding, kidney or liver disease, and any previous reaction to this ingredient or its drug class.
This page provides an educational overview of Ticagrelor and does not replace medical advice, diagnosis, product labelling, or prescribing instructions. Individual products can differ in active ingredient combinations, strength, formulation, storage, route, and monitoring requirements. Do not start, stop, switch, or combine medicines based only on this catalog page; use the specific product label and guidance from a qualified healthcare professional.